Brendan Teehan Acadia Pharmaceuticals Inc (ACAD) insider trading activity

Brendan Teehan is EVP, COO, HEAD OF COMMERCIAL of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 62,105 shares of ACAD, which is worth approximately $1.07 Million. The most recent transaction as insider was on Nov 19, 2024, when has been sold 10,329 shares (Common Stock) at a price of $16.81 per share, resulting in proceeds of $173,630. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.1K

19.03% 3M change

104.34% 12M change

Total Value Held $1.07 Million

Brendan Teehan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 19 2024	SELL Open market or private sale	$173,630 $16.81 p/Share	10,329 Reduced 14.26%	62,105 Common Stock
Nov 17 2024	BUY Exercise of conversion of derivative security	-	19,826 Added 21.49%	72,434 Common Stock
Aug 19 2024	SELL Open market or private sale	$145,679 $15.28 p/Share	9,534 Reduced 15.45%	52,177 Common Stock
Aug 16 2024	BUY Grant, award, or other acquisition	-	18,653 Added 23.21%	61,711 Common Stock
May 02 2024	SELL Open market or private sale	$58,900 $16.94 p/Share	3,477 Reduced 7.62%	42,133 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	6,814 Added 13.0%	45,610 Common Stock
Apr 08 2024	SELL Open market or private sale	$45,890 $17.87 p/Share	2,568 Reduced 6.21%	38,796 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	5,024 Added 10.83%	41,364 Common Stock
Mar 27 2024	SELL Open market or private sale	$92,005 $17.9 p/Share	5,140 Reduced 12.39%	36,340 Common Stock
Mar 25 2024	BUY Grant, award, or other acquisition	-	10,048 Added 19.5%	41,480 Common Stock
Feb 26 2024	SELL Open market or private sale	$15,394 $24.67 p/Share	624 Reduced 1.95%	31,432 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	1,107 Added 3.34%	32,056 Common Stock
Jan 08 2024	SELL Open market or private sale	$21,900 $29.96 p/Share	731 Reduced 2.31%	30,949 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	1,287 Added 3.9%	31,680 Common Stock
Nov 20 2023	SELL Open market or private sale	$112,294 $22.64 p/Share	4,960 Reduced 14.03%	30,393 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	9,912 Added 21.9%	35,353 Common Stock
May 17 2023	SELL Open market or private sale	$334,552 $22.5 p/Share	14,869 Reduced 37.91%	24,356 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	29,738 Added 43.12%	39,225 Common Stock
May 01 2023	SELL Open market or private sale	$11,606 $21.18 p/Share	548 Reduced 5.46%	9,487 Common Stock
Apr 29 2023	BUY Exercise of conversion of derivative security	-	1,567 Added 13.51%	10,035 Common Stock
Apr 06 2023	SELL Open market or private sale	$31,798 $18.16 p/Share	1,751 Reduced 17.13%	8,468 Common Stock
Apr 05 2023	BUY Exercise of conversion of derivative security	-	5,024 Added 32.96%	10,219 Common Stock
Feb 24 2023	SELL Open market or private sale	$8,657 $18.78 p/Share	461 Reduced 8.15%	5,195 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	1,107 Added 16.37%	5,656 Common Stock
Jan 09 2023	SELL Open market or private sale	$9,113 $17.13 p/Share	532 Reduced 10.47%	4,549 Common Stock

Brendan Teehan

EVP, COO, HEAD OF COMMERCIAL

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account